Those with chronic obstructive pulmonary disease (COPD) may be more likely to suffer from a heart attack or stroke following an acute exacerbation if they have a history or at risk of cardiovascular disease (CVD).
Those with chronic obstructive pulmonary disease (COPD) may be more likely to suffer from a heart attack or stroke following an acute exacerbation if they have a history or at risk of cardiovascular disease (CVD).
According to new research, within the 30-day period following an acute exacerbation, heart attack or stroke odds are 4 times as likely. This was determined through an analysis of data from the Study to Understand Mortality and MorbidITy (SUMMIT) trial. The trial included patients who were previous or current smokers, 40 to 80 years old, have CVD or at risk for CVD, have a forced expiratory volume in 1 second of 50% to 70% of predicted, and a forced vital capacity of below or equal to 70%.
The data analysis resulted in the researchers attempting to identify the best interventions to study for after a COPD exacerbation in those with CVD.
“One approach might be to study currently used cardiac medications, such as antiplatelet agents, statins and/or beta-blockers immediately following COPD exacerbations,” Ken M. Kunisaki, MD, MS, the lead study author and associate professor of medicine at the University of Minnesota and Minneapolis VA Health Care System, said in a statement. “Another approach might be to use experimental drugs that specifically reduce inflammation.”
Because no interventions have been discovered, Kunisaki recommends that patients who recently experienced a COPD exacerbation and are noticing heart attack symptoms should seek care immediately and contact their care providers.
“One theory for why this happens is that COPD triggers inflammation and that, in turn, leads to CVD,” Kunisaki said in a statement. “Because COPD exacerbations lead to particularly high levels of inflammation, we wondered if these exacerbations would be linked to higher rates of CVD events.”
Exploring Possibilities in Disease Modification in MPNs
October 25th 2024Experts are asking whether the study and treatment of myeloproliferative neoplasms (MPNs) is ready for a new era with new end points, with data that show how survival benefits are biologically linked to changes in the spleen, reduction in fibrosis, or other responses.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Prediagnosis Diet Improves Survival in Black Women With Deadly Ovarian Cancer
October 24th 2024Moderate prediagnosis adherence to dietary guidelines was associated with improved survival rates among Black women with high-grade serous ovarian cancer, the most common and lethal type of ovarian cancer.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
Rozanolixizumab Effective in Patients with MuSK MG, Analysis Shows
October 23rd 2024A new subgroup analysis of patients with muscle-specific tyrosine kinase (MuSK) autoantibody-positive (Ab+) myasthenia gravis (MG) shows rozanolixizumab (Rystiggo) contributes to meaningful symptom improvement.
Read More
FIT Completion, Yield Rates in CRC Screening Similar After New Screening Guidelines
October 22nd 2024Patients were found to have similar completion and yield rates for the fecal immunochemical test (FIT) at both 45 years and 50 years, making screening for colorectal cancer (CRC) effective in younger patients.
Read More